Study to Assess the Safety and Tolerability of Repeated Doses of an Investigational New Drug in Patients With Cancer and Cachexia
Study to Assess the Safety and Tolerability of Repeated Doses of an Investigational New Drug in Patients
With Cancer and Cachexia. A Phase 1B, 12-Week, Open-Label Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Following Repeated Subcutaneous Administrations of PF-06946860 in Patients With Cancer and Cachexia.
Category & Conditions: Cancer
Medicine: PF-06946860
ClinicalTrials.gov Identifier (NCT): NCT04299048
Protocol ID: C3651009
PrintDownloadOpen Plain Language Summary Result: Click here